6th Jul 2022 17:23
RTW Venture Fund Ltd - New York-based investor in life sciences, biopharmaceutical, and medical technology companies - Portfolio firm Orchestra BioMed closes USD110 million Series D funding round, and plans to list on Nasdaq through venture of RTW-sponsored firm Health Sciences Acquisitions Corp 2.
Equity financing and business merger is expected to generate at least USD180 million in proceeds, which will go toward funding the combined firm into 2026.
Current stock price: USD1.00
12-month change: down 52%
By Dayo Laniyan; [email protected]
Copyright 2022 Alliance News Limited. All Rights Reserved.
Related Shares:
Rtw Biotech